OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Rheumatology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Inflammatory arthritis affects men’s fertility	621
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	407
Bimekizumab effective across the axSpA spectrum	351
No benefit from adding MTX to ustekinumab	337
Low-dose rituximab can go even lower	308
Genome-wide mutagenesis reported in systemic sclerosis	261
Rheumatic diseases on the rise	235
A role for TGFβ and EBV in MIS-C pathogenesis	215
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	205
Biological and clinical roles of IL-18 in inflammatory diseases	186
Targeting articular Mmp13 in OA	175
New drug formulation reduces bone loss	172
FOXP3 splice variant is associated with autoimmune disease	168
Towards better management of sterile bone inflammation	153
Use of platelet-rich plasma for knee OA not supported by RCT results	152
MIS-C: myths have been debunked, but mysteries remain	151
Inflammation across tissues: can shared cell biology help design smarter trials?	148
Which NSAIDs are best for OA treatment?	132
The 2022 ACR vaccination guideline: a call-to-action	121
Urchin-like nanoparticles for miRNA therapy of OA	121
2021 ACR guideline for JIA reflects changes in practice	121
The value of comparative efficacy studies in informing rheumatology guidelines	120
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	113
Down syndrome: insights into autoimmune mechanisms	109
To choose or not? The value of discrete-choice experiments in rheumatology	109

Ageing stem cells hold the key to age-related bone degeneration	104
Appraising the evolving landscape of protease inhibition in osteoarthritis	100
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	99
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	97
Co-trimoxazole reduces mortality in anti-MDA5-DM	97
Low-dose glucocorticoids benefit seniors with RA	95
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	93
Wnt-induced IGF1 drives OA	93
Calprotectin tracks tocilizumab-treated RA	93
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	89
Author Correction: Proposals for the rheumatological use of JAK inhibitors	88
Guiding ILD management in systemic autoimmune rheumatic diseases	87
A direct link between SARS-CoV-2 and bone loss	84
Rheumatic diseases and metabolism: where centre and periphery meet	83
Fumarate drives interferon release in systemic sclerosis monocytes	82
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	80
Low back pain is a growing concern	80
Rheumatology in the digital health era: status quo and quo vadis?	78
S100A4 inhibition targets fibrosis in SSc	77
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	76
Pain in systemic lupus erythematosus: emerging insights and paradigms	75
sCD13 role in arthritis mediated via bradykinin receptor	74
Targeting the IVD clock to halt degeneration	71
Antibiotics keep rheumatic heart disease at bay	71
Erosive cargo from synovial fibroblasts	70
Which DMARD for ICI-associated arthritis?	68
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	68
ERAP1 and the return of the UPR in ankylosing spondylitis	66
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	66
PGE2 receptor antagonist has potential to treat osteoarthritis	65
CAR T cells induce drug-free SLE remission	64
Macrophage-coated nanocarriers for gouty arthritis	63
A path towards personalized medicine for autoinflammatory and related diseases	59
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	59
Blocking CDK7 attenuates inflammatory arthritis	58
Insights into IVDD pathogenesis in 2024	58
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	58
PPIs linked to increased risk of knee replacement	56
RA risk from occupational inhalation	55
Two sides of management recommendations for psoriatic arthritis	54
TASL has a key role in SLE	54
Improving the design of RCTs in non-radiographic axial spondyloarthritis	52
Repolarizing macrophages using antagomirs	51
All fibroblasts are equal, but some are more equal than others	51
A leading role for interferon as a treatment target in Sjögren syndrome	50
New refinements aim to optimize articular cartilage tissue engineering	50
Profiling joint tissues at single-cell resolution: advances and insights	48
New hope for B cell-targeting therapy in pSS	47
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	47
New developments in electronic health record analysis	46

Piezo1 induces new bone formation in AS	45
A critical view of WHO guidelines on management of low back pain	45
Platelets as drivers of immunothrombosis in rheumatic diseases	45
Author Correction: Glycobiology of rheumatic diseases	44
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	43
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	42
AhR promotes suppressor cell function in Sjögren syndrome	41
APOE in fat pad and synovium contributes to knee OA	41
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	39
Treg cell-inducing nanoparticles show promise for treating OA	39
Sex- and gender-based personalized medicine in rheumatology	39
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	38
Pathogenic antibodies target stromal antigens in RA	36
CXCL5 effective in mouse model of SLE	36
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	35
Stromal cells implicated in RA genetic risk	35
HLA autoimmunity risk alleles influence T cell receptor sequences	32
Imaging for prediction of RA development	32
New OA risk factors and drug targets revealed	31
BiTE therapy for rheumatic diseases	30
Shifting the SLE management paradigm: challenges and implications	30
Critical appraisal of serum urate targets in the management of gout	29
FABP4 exacerbates RA	29
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	28
Post-transcriptional checkpoints in autoimmunity	28
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	27
Location-specific treatment of chronic inflammatory joint disease	27
Mechanisms and clinical implications of intervertebral disc calcification	26
Parathyroid hormone receptor agonists in the management of osteoporosis	26
Guselkumab effective through 2 years in PsA trial	25
COVID-19 linked to rise in anti-MDA5 autoimmunity	25
Detachment promotes RA synovial fibroblast survival and invasiveness	24
PLG nanoparticles target inflammatory monocytes in SSc	23
Multi-omics reveals distinct MPA subtypes	22
Complement therapeutics are coming of age in rheumatology	21
Adropin inhibits fibrosis in SSc	21
Notch signalling mediates OA pain in mice	21
Busting the myth of methotrexate chronic hepatotoxicity	20
State-of-the-art evidence in the treatment of systemic sclerosis	20
The potential contribution of in silico studies to improved treatment of osteoarthritis	19
Citrulline immunity in RA: CD8+ T cells enter the scene	19
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	19
How the COVID-19 pandemic has affected rheumatology research	19
Synovial fluid as a complex molecular pool contributing to knee osteoarthritis	18
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells	18
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	17
Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms	17
Treatment of non-systemic juvenile idiopathic arthritis	17
UNC93B1 variants promote SLE via TLR activation	16
Primary care rheumatology: towards sustainable development in health	16
Bone-modifying drugs slow OA progression	16
Shedding light onto the immunometabolic effects of glucocorticoids	16
Update on the pathophysiology and treatment of primary Sjögren syndrome	16
Undiagnosed axSpA is prevalent in IBD	16
The immune health metric as an indicator of health and disease	16
No benefit to intensive urate lowering in gout	15
Combination therapy for Behçet uveitis	15
The PU.1– IL-9 axis in TH9 cells promotes RA	15
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	15
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	14
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	14
More than a leaky gut: how gut priming shapes arthritis	14
Glycosylation switch in synovial fibroblasts promotes ECM degradation	14
Interleukin-2 and regulatory T cells in rheumatic diseases	13
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	13
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications	13
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	13
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	13
Reversal of inflammatory priming prevents arthritic flares	13
Advances in the calculation of minimal important change estimates for patient-reported outcome measures	12
T cell differentiation in Sjögren syndrome is regulated by TOX	12
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	12
Paediatric glucocorticoid toxicity index: new possibilities in assessment	12
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	12
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	12
Disease stratification in GCA and PMR: state of the art and future perspectives	11
Novel TLR7 variant causes lupus	11
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies	11
Evidence-Based Guideline for the management of osteoporosis in men	11